All In Biotech

Drug Trial Radar · NCT04586335

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

24

Actual

Start

Sep 28, 2020

Primary completion

Feb 15, 2023

Study completion Feb 15, 2023

Sponsor

Lead sponsor
Haihe Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior PARP inhibitor, and in patients with recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer who are platinum resistant or refractory. The study will assess if this combination will optimize anti-tumor activity, block tumor growth and overcome the resistance to PARP inhibitor treatment. The study consists 2 parts. In Part 1 dose escalation, the objective is to determine the maximum toleration dose (MTD) of the combination. The final recommended phase 2 dose (RP2D) of CYH33 in combination with olaparib will be based on the totality of an overall assessment of available safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy which could be the MTD or a dose level lower in specific cohorts of patients. In Part 2 dose expansion, the main objective is to evaluate the efficacy at RP2D.

Conditions

  • Ovarian Cancer
  • Breast Cancer
  • Solid Tumor
  • Prostate Cancer
  • Endometrial Cancer

Interventions

  • CYH33Drug

    Clinical Activity of CYH33, an Oral α-specific PI3K Inhibitor in Combination with Olaparib, an Oral PARP Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: 12 months
  2. Tumor objective response rate (ORR)Time frame: 38 months

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut

  • UT Southwestern: Simmons Cancer Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Scientia Cancer Centre

    Sydney, New South Wales, Australia

  • Integrated Oncology Network PTY LTD

    Brisbane, Queensland, Australia

  • Monash Cancer Centre

    Melbourne, Victoria, Australia

  • Fudan University - Pudong Medical Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.